Skip to Main Content
Beta test
our new site.
(
NLM Technical Bulletin
)
Home
Search
Study Topics
Glossary
Full Text View
Tabular View
No Study Results Posted
Related Studies
Bortezomib and Azacitidine in Treating Patients With Relapsed or Refractory T-Cell Lymphoma
This study is ongoing, but not recruiting participants.
Study NCT01129180 Information provided by Ohio State University Comprehensive Cancer Center
First Received on May 17, 2010. Last Updated on February 18, 2013
History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Anaplastic Large Cell Lymphoma
Angioimmunoblastic T-cell Lymphoma
Hepatosplenic T-cell Lymphoma
Peripheral T-cell Lymphoma
Prolymphocytic Leukemia
Small Intestine Lymphoma
Additional conditions recognized in this trial
Immunoblastic Lymphadenopathy
Leukemia
Leukemia, Large Granular Lymphocytic
Leukemia, Prolymphocytic
Leukemia, T-Cell
Leukemia-Lymphoma, Adult T-Cell
Lymphoma
Lymphoma, Extranodal NK-T-Cell
Lymphoma, Large-Cell, Anaplastic
Lymphoma, Non-Hodgkin
Lymphoma, T-Cell
Lymphoma, T-Cell, Cutaneous
Lymphoma, T-Cell, Peripheral
Lymphoproliferative Disorders
Mycoses
Mycosis Fungoides
Sezary Syndrome
More general conditions related to this trial
Immune System Diseases
Immunoproliferative Disorders
Leukemia, Lymphoid
Lymphatic Diseases
Neoplasms
Neoplasms by Histologic Type
Interventions listed in this trial
azacitidine
bortezomib
Correlative studies
More general drug interventions related to this trial
Antimetabolites
Antimetabolites, Antineoplastic
Antineoplastic Agents
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Protease Inhibitors
Therapeutic Uses
Sponsors listed in this trial
Pierluigi Porcu
Millennium Pharmaceuticals, Inc.
Celgene Corporation
Back to top of Main Content
